Business Description
Lumos Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US6515111077
Description
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.6 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -18.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 116 | |||||
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -65 | |||||
| 3-Year FCF Growth Rate | -4 | |||||
| 3-Year Book Growth Rate | -37.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 33.34 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.07 | |||||
| 9-Day RSI | 48.9 | |||||
| 14-Day RSI | 53.77 | |||||
| 6-1 Month Momentum % | 89.18 | |||||
| 12-1 Month Momentum % | 44.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.66 | |||||
| Quick Ratio | 2.66 | |||||
| Cash Ratio | 2.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.8 | |||||
| Shareholder Yield % | -0.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1647.57 | |||||
| Net Margin % | -1583.49 | |||||
| FCF Margin % | -1436.42 | |||||
| ROE % | -182.95 | |||||
| ROA % | -112.43 | |||||
| ROIC % | -1090.37 | |||||
| ROC (Joel Greenblatt) % | -8432.92 | |||||
| ROCE % | -143.84 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.99 | |||||
| PB Ratio | 7.57 | |||||
| Price-to-Tangible-Book | 7.54 | |||||
| EV-to-EBIT | -0.66 | |||||
| EV-to-EBITDA | -0.66 | |||||
| EV-to-Revenue | 10.81 | |||||
| EV-to-Forward-Revenue | 11.62 | |||||
| EV-to-FCF | -0.75 | |||||
| Price-to-Median-PS-Value | 1.23 | |||||
| Price-to-Net-Current-Asset-Value | 7.82 | |||||
| Price-to-Net-Cash | 39.09 | |||||
| Earnings Yield (Greenblatt) % | -151.52 | |||||
| FCF Yield % | -85.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LUMO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lumos Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.205 | ||
| EPS (TTM) ($) | -4.29 | ||
| Beta | -0.43 | ||
| Volatility % | 118.38 | ||
| 14-Day RSI | 53.77 | ||
| 14-Day ATR ($) | 0.114321 | ||
| 20-Day SMA ($) | 4.334455 | ||
| 12-1 Month Momentum % | 44.7 | ||
| 52-Week Range ($) | 1.3701 - 4.5756 | ||
| Shares Outstanding (Mil) | 8.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lumos Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lumos Pharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lumos Pharma Inc Frequently Asked Questions
What is Lumos Pharma Inc(LUMO)'s stock price today?
The current price of LUMO is $4.30. The 52 week high of LUMO is $4.58 and 52 week low is $1.37.
When is next earnings date of Lumos Pharma Inc(LUMO)?
The next earnings date of Lumos Pharma Inc(LUMO) is 2025-03-07 Est..
Does Lumos Pharma Inc(LUMO) pay dividends? If so, how much?
Lumos Pharma Inc(LUMO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers